Ryan Specialty Holdings, Inc. (NYSE: RYAN) — Cheapest Since Its IPO as the Hard Market Softens: A Secular E&S Compounder That Levered Into Property Right at the Peak

Report date: 2026-07-10 · Coverage: Initiation Price (2026-07-09 close): ~$40.61 · Diluted market cap: ~$11.3B · Diluted enterprise value: ~$14.7B (net debt ~$3.2B, ~3.3x adj. EBITDAC) FY2025: revenue $3,051.1M (+21%) · organic +10.1% · adj. EBITDAC $966.7M (31.7% margin) · adj. dil. EPS $1.96 (+9.5%) · GAAP EPS $0.47 (Up-C — not meaningful)

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information — not investment advice. The analysis that follows takes no position and carries no price target; this block is the single exception.

Verdict: HOLD / accumulate-on-weakness — a genuinely high-quality, capital-light specialty distributor mid a real cyclical inflection, de-rated to its cheapest valuation since the IPO. Accumulate in tranches here at ~$40 and add toward the low-$30s (near the $29 May-2026 trough); base-case fair-value zone ~$48–56 (≈18–19x FY27 adjusted EPS of ~$2.55, ~14–16x EV/adj-EBITDAC) if the cycle stabilizes. Not a short — you don’t short a founder-controlled, 32%-margin, secular-E&S-tailwinded franchise into a cyclical trough while the founder is signaling “dislocation.” Conviction: medium.

Tag: “A wide-open secular runway meets a rolling-over rate cycle — cheapest since IPO, but it bought property-cat at the top.”

Ryan Specialty is a genuinely good business caught in a genuinely bad part of its cycle, priced as if the bad part is permanent. The franchise is excellent: the #2 U.S. wholesale broker and #1 U.S. managing underwriter, a capital-light, ~32%-adjusted-EBITDAC-margin, ~117%-FCF-conversion distribution machine that takes no underwriting risk, riding the single best structural tailwind in insurance — the secular migration of business from the admitted market into Excess & Surplus (E&S), whose share of U.S. commercial premium has climbed from ~5% to ~24% and which has grown ~10.6%/year for a decade largely independent of pricing. Half its revenue is now higher-margin, stickier delegated authority (binding + managing-underwriter programs), a meaningful counter-cyclical offset. It is founder-built (Pat Ryan, who founded Aon), founder-controlled, and the founder is putting his own capital to work at these prices.

The problem is that RYAN is also the most property-cat-rate-cyclical of the major brokers, and that cycle has rolled over hard. After two benign hurricane seasons, carriers are flush and “buying market share”: large, cat-exposed E&S property accounts are down 25–35%, capacity is flooding in, and RYAN’s wholesale book is a straight-commission business that “rises and falls with pricing.” The result is a textbook growth-multiple de-rating meeting a real slowdown: organic growth decelerated from ~15% (2023) to +10.1% (2025), management cut FY2026 guidance twice — now to ~5% organic with Q2 guided “near zero” and adjusted EBITDAC margins down ~100–150bps — and deferred its 35%-margin target indefinitely. From an April-2025 all-time high of ~$75, the stock fell ~61% to ~$29 before bouncing to ~$40, now ~46% off its high and at the 14th percentile of its (short) valuation history. And management poured fuel on the timing: it spent ~$1.7B on two large property-cat MGUs (US Assure, Velocity) at peak multiples, debt-funded, right as the cat cycle turned — doubling leverage to ~3.3–3.5x just as EBITDAC growth slowed.

Framing: de-rated GARP with a cyclical-trap caveat. On the numbers it is the cheapest broker growth-adjusted — ~14.7x EV/adj-EBITDAC and ~20x adjusted EPS for a business that still out-grows AJG and Marsh, which trade richer. The factor tape confirms an abandoned low-vol quality name (beta 0.30, deeply negative momentum, name-specific drawdown), not a high-beta bubble. But the discount is partly rational (Marathon capital-cycle: the hard market attracted the very capacity now competing rate away, so peak organic and margins deserve a haircut before you extrapolate), and there are real fish-hooks the headline adjusted EPS hides — a $459M tax-receivable-agreement liability plus NCI cash distributions that leak value below the Class-A line, 77% founder voting control that leaves minority holders little say, and a President forced out amid the inflection. This is a good franchise you want to own, bought at a cyclical low — provided you underwrite the cycle, not the peak.

What flips me decisively bullish: property E&S rates stabilizing or re-firming (Pat Ryan’s own “one big storm away from adjustments”) with organic reaccelerating and leverage tracking below ~3x. What flips me bearish: organic settling at mid-single-digits with margins still contracting into 2027 (the cyclical peak was structural), or a poorly-timed integration stumble on the property MGUs bought at the top. At ~$40 you are paid to wait; I’d rather accumulate into the low-$30s where the cycle risk is more fully in the price.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are Fact; attributed drivers are Interpretation. (RYAN has only traded since its July-2021 IPO.)

RYAN is a full round-trip: it IPO’d at $23.50 (~$27 first close) in July 2021, rode the E&S hard market to an all-time high of ~$74.92 (Apr-3-2025), then de-rated ~61% to a 52-week low of ~$29.27 (May-6-2026) before bouncing to ~$40.61 — ~46% off the high but ~39% off the trough. Spot sits just below the 200-day EMA (~$42.8) and above the 21-day (~$36). Beta is 0.30 — a low-beta name whose drawdown is name/cycle-specific (idiosyncratic vol ~0.36), not a market event.

Cycle narrative. (1–3) RYAN IPO’d into the hard market, popped, and then chopped through the 2022 rate-hike bear as its low beta provided ballast. (4–6) The 2024 up-leg is where the excess built: ~20% growth, aggressive MGU expansion, and a peak hard-market narrative carried the stock +80% to an all-time ~$75 in April 2025 at its richest-ever multiple. (7) The dominant move is the ~61% peak-to-trough collapse through 2025–2026 as the property-cat pricing cycle turned (rates down 25–35%), organic growth decelerated, and management cut FY2026 guidance twice to ~5% organic with margins contracting — a growth-multiple de-rating meeting a genuine slowdown, amplified by a broad early-2026 broker-sector “AI-disruption” scare. (8) A ~39% bounce off the May-2026 low (helped by the Onex sponsor overhang finally clearing) leaves it ~46% off its high. (Price moves are FACT from the price series since IPO; drivers are INTERPRETATION cross-referenced to earnings dates, guidance cuts, and 8-K events. The big moves were pricing-cycle and multiple events on a still-growing franchise.)

1. Executive Summary

Ryan Specialty is a specialty-insurance distribution firm — a wholesale intermediary sitting between retail brokers and insurance carriers, focused on hard-to-place / Excess & Surplus (E&S) risk. It takes no underwriting risk; revenue is commissions and fees. It is the #2 U.S. wholesale P&C broker and the #1 U.S. managing underwriter, serving >35,000 retail firms and >350 carriers. FY2025 revenue was $3.05B (+21%) across three specialties: Wholesale Brokerage $1,600.4M (53.4%, +7.5%), Binding Authority $370.2M (12.4%, +15.5%), and Underwriting Management $1,024.0M (34.2%, +58.5% — mostly inorganic). “Delegated authority” (binding + underwriting management) is now ~47% of revenue — the higher-margin, stickier, counter-cyclical half.

The quality of the business is not in doubt. It is capital-light and high-return: adjusted EBITDAC margin ~32%, adjusted EPS $1.96 (+9.5%), ~117% free-cash-flow conversion of adjusted net income, on negligible tangible capital. And it rides the best structural tailwind in insurance — the secular migration to E&S, whose share of U.S. commercial premium has risen from ~5% (pre-2019) to ~24%, growing ~10.6%/year for a decade largely independent of the pricing cycle (driven by social inflation, catastrophe/climate risk, cyber, and complex/emerging exposures). This is a genuine, if narrow-to-moderate, moat: scale in the E&S niche, the Ryan brand and producer talent, and — deepest — the sticky delegated-authority relationships of the managing-underwriter book.

But RYAN is the most property-cat-rate-cyclical of the major brokers, and that cycle has turned. After two benign hurricane seasons, carriers are flush and competing on price: large cat-exposed E&S property accounts are down 25–35%, and RYAN’s wholesale book is straight-commission — it “rises and falls with pricing.” Organic growth decelerated from ~15% (2023) to +10.1% (2025), and on the Q1-2026 call management cut FY2026 organic guidance to ~5% (Q2 “near zero”) with adjusted EBITDAC margins guided down ~100–150bps, and deferred its 35%-margin target indefinitely. Worse for the timing: RYAN spent ~$1.7B on two large property-cat MGUs (US Assure ~$1.18B, Velocity ~$569M) at peak multiples, debt-funded, right as the cat cycle turned — doubling net leverage to ~3.3–3.5x adjusted EBITDAC just as EBITDAC growth slowed.

The stock has de-rated to its cheapest valuation since the IPO. From an April-2025 high of ~$75, it fell ~61% to ~$29 before bouncing to ~$40 — ~46% off the high, the 14th percentile of its own valuation history. At ~14.7x EV/adjusted-EBITDAC and ~20x adjusted EPS, it trades at a discount to slower-growing AJG and Marsh despite the fastest growth in the group — growth-adjusted, the cheapest broker. The factor tape reads an abandoned low-vol quality name (beta 0.30, deeply negative momentum), not a falling knife.

The forward question is whether you are catching a cyclical trough on a durable-secular franchise, or extrapolating a peak. The bull owns a capital-light, 32%-margin, secular-E&S compounder at a cyclical low with founder alignment ($40M buyback, Pat Ryan’s self-funded option grant citing “dislocation”) and a cleared sponsor overhang. The bear notes that the discount is partly rational (the hard market attracted the capacity now competing rate away), that management levered up for property MGUs at the top, that a $459M tax-receivable-agreement liability plus NCI distributions leak value below the adjusted-EPS line, and that 77% founder voting control leaves minority holders little say. No recommendation or price target appears below; valuation is treated as embedded expectations and scenarios.

2. Business Overview (§7.1)

What RYAN is. Founded in 2010 by Patrick Ryan (founder and former CEO of Aon) and public since July 2021, Ryan Specialty is a wholesale specialty-insurance intermediary — it sits between retail insurance brokers (who own the client relationship) and insurance carriers (who take the risk), placing complex, hard-to-place, and Excess & Surplus (E&S / “non-admitted”) risks. It takes no underwriting risk of its own (bar a small Geneva Re equity-method stake); revenue is commissions and fees on the premium it places or the programs it manages. It is the #2 U.S. wholesale broker and #1 U.S. managing underwriter by 2024 premium.

Three specialties (FY2025 net commissions & fees $2,994.6M) [FACT — FY2025 10-K]:

• Wholesale Brokerage — $1,600.4M (53.4%), +7.5% organic. Places complex specialty P&C risk with carriers (RT Specialty, executive/professional liability). This is the most pricing-cyclical leg (heavy property-cat exposure).
• Binding Authority — $370.2M (12.4%), +15.5%. Delegated binding on smaller, more standardized E&S risks — faster-growing, stickier.
• Underwriting Management — $1,024.0M (34.2%), +58.5% (mostly inorganic). MGUs/MGAs with delegated underwriting authority from carriers, earning fees plus profit commissions. The highest-margin, stickiest, most secular leg — but the jump from 26% to 34% of mix was bought (US Assure, Velocity, Castel, Innovisk), not organic.

Delegated authority (binding + underwriting management) is now ~47% of revenue — the counter-cyclical, higher-margin half that diversifies away from raw wholesale pricing. Contingent/profit commissions within it actually rise as loss ratios improve in a softening market — a partial hedge.

Organic growth (the headline KPI): ~15.4% (2023) → ~12.8% (2024) → +10.1% (2025), with Q1-2026 ~11–12% flattered by the Ryan Re/Markel renewal (the largest renewal falls in Q1). Management has guided FY2026 organic down to ~5% (“either side of 5%”), with Q2 “near zero.”

Verdict (§7.1). A capital-light, high-margin, high-recurring specialty-distribution leader with a genuinely diversified three-leg model (wholesale, binding, underwriting management) and the best structural tailwind in insurance — but a wholesale core that is highly exposed to the property-cat pricing cycle now rolling over.

3. Industry Dynamics (§7.2)

The secular story (durable). The dominant structural driver is the migration of business from the admitted/standard market into E&S. U.S. E&S direct premium reached ~$130B in 2024, growing at a ~10.6% CAGR (2010–2024) versus ~4.4% for the admitted market, lifting E&S from ~13.5% to ~25.7% of commercial premium — driven by social inflation, catastrophe/climate risk, cyber, and complex/emerging exposures that the admitted market cannot or will not price. This flow benefits scaled wholesalers like RYAN, Amwins, and CRC largely independent of the pricing cycle — it is a share-shift, not a rate story. Management frames it as “flow > rate.”

The cyclical story (rolling over). Layered on top was the 2020–2024 hard market — rate and exposure growth — which is now turning. Property-cat E&S rates are down 25–35% after two benign hurricane seasons left carriers profitable and eager to redeploy capital; abundant reinsurance and alternative (ILS) capital is flooding in. Casualty is bifurcated — high-hazard lines (transportation, habitational, healthcare, public entity) are still firming (+10%+), but small/medium hazard is softening as carriers redeploy property profits. AM Best cut its U.S. E&S outlook from positive to stable (Nov-2025).

Structure and capital cycle. The wholesale top is a concentrated oligopoly (Amwins #1 private, CRC private, RYAN #2 / #1 managing underwriter). The Marathon capital-cycle read carries two yellow flags: (1) the hard market attracted the very reinsurance/ILS capacity now competing rate away — a classic supply response mean-reverting returns; and (2) private-equity-funded MGA proliferation is fragmenting the delegated-authority space and inflating acquisition multiples. Both argue for a haircut to peak organic and margins before extrapolation.

Verdict (§7.2): structurally good industry at a less-favorable point in the cycle. The secular E&S flow is a genuine, durable, decade-long tailwind that makes wholesale distribution attractive. But the cyclical pricing kicker that supercharged 2020–2024 has turned, and RYAN’s straight-commission model is directly exposed. Good industry, wrong part of the cycle.

4. Competitive Position (§4 / §7.3)

A genuine but narrow-to-moderate moat. In Greenwald’s taxonomy RYAN combines economies of scale in the E&S niche (carriers and retailers concentrate flow on a few large, expert wholesale partners; panel consolidation favors scale), intangibles (the Ryan brand and producer talent, delegated-authority underwriting IP and data), and switching/search costs (retailers value consistent market access; carrier delegated-authority relationships are contractual and sticky). The moat is deepest in Underwriting Management/MGU — delegated authority is sticky, exclusive programs and profit-commission alignment bind carrier and manager, and the data/underwriting IP compounds. It is shallowest in Wholesale Brokerage, which is more contestable.

Financial proof. The moat shows up as a durable ~32% adjusted-EBITDAC margin and (until the cycle turned) double-digit organic growth on a capital-light base with ~117% FCF conversion — economics that scale.

The pressure tests are real [FACT — 10-K risk factors + industry structure]:

• Retail brokers internalizing E&S (AJG, BRO, BRP building or buying wholesale/MGA capabilities) — disintermediation from above.
• Carriers pulling delegated authority or going direct (the 10-K explicitly flags disintermediation risk) — the MGU relationship is only as durable as the carrier’s appetite.
• MGA proliferation (PE-funded) fragmenting the space and competing for talent and programs.
• Greenwald’s caveat that fast market growth erodes scale barriers — a booming E&S market invites entrants.

Versus peers. RYAN’s wholesale scale rivals private Amwins (#1) and CRC; its managing-underwriter leadership is a genuine differentiator. Versus retail brokers BRO/AJG, RYAN is more specialized and faster-growing but more pricing-cyclical and less diversified by line/geography. The moat is real but not wide — the wholesale leg is contestable, the MGU leg more defensible.

Verdict (§7.3): a high-quality, capital-light distribution compounder with a genuine but moderate moat. Its recent growth blended structural (secular E&S flow + share gains + MGU mix-shift) with cyclical (hard-market pricing) — the latter now fading, the former intact. The MGU book is the durable core; the wholesale book is the cyclical, contestable edge. Not a wide moat, but a real one — and the market is testing it precisely as the cycle turns.

5. Growth History and Forward Opportunities (§5 / §7.4)

History. Revenue compounded from $1.43B (2021) to $3.05B (2025) — a ~21% CAGR, roughly half organic and half acquired. Organic growth ran mid-teens through the hard market and has decelerated: ~15.4% (2023) → ~12.8% (2024) → +10.1% (2025). Adjusted EPS grew to $1.96 (+9.5% in FY2025). Delegated authority (binding + MGU) doubled to ~47% of revenue in two years, much of it bought.

The near-term inflection. On the Q1-2026 call, management cut FY2026 organic guidance to ~5% (Q2 “near zero”) and guided adjusted EBITDAC margin down ~100–150bps, embedding property-cat E&S rate declines of 25–35% and rising casualty competition. The 35%-margin target was deferred indefinitely. This is a genuine slowdown, not merely optics.

Forward drivers (the bull’s case for durability):

• Secular E&S flow (+~8%): the admitted→E&S migration continues largely independent of rate — the durable growth spine.
• Delegated authority / MGU (47% of revenue): higher-margin, stickier, with contingent commissions that rise as loss ratios improve in a soft market — a counter-cyclical offset.
• Share gains and panel consolidation: scale wholesalers win as carriers and retailers concentrate flow.
• M&A: a proven sourcing engine (~$2.7B/12 deals in 2023–25) with a long fragmented runway — though now to be funded from a more levered balance sheet.
• Cyclical optionality: a single major catastrophe season would re-firm property rates (Pat Ryan: “one big storm away from adjustments”).

Verdict (§5/§7.4): durable secular growth, temporarily overwhelmed by a cyclical rate reversal. The secular E&S flow and the counter-cyclical delegated-authority book are real and durable; the near-term organic collapse to ~5% is a property-pricing-cycle event. The question is whether organic troughs at mid-single-digits and reaccelerates (cyclical) or the peak growth was a one-time hard-market artifact (structural). The Q2-2026 “near zero” print will be the tell.

6. Financial Quality (§7.5)

Use adjusted metrics — GAAP is meaningless here. The Up-C structure splits GAAP net income ($214.2M FY25) between Class A holders and the non-controlling LLC-unit holders (Ryan/management/pre-IPO owners), leaving GAAP diluted EPS of ~$0.47 that reflects only the Class-A slice. The economically-correct figures (FY25/24/23):

• Adjusted EBITDAC: $966.7M / $811.2M / $624.7M; margin 31.7% / 32.2% / 30.1% (note margin ticked down in FY25 — an early sign of pricing pressure).
• Adjusted diluted EPS: $1.96 / $1.79 / $1.38 (+9.5% FY25), on a fully-exchanged ~279M share count (138.2M Class A + 135.4M LLC units + 5.4M awards).
• Revenue $3.05B (+21%); CFO $643.7M; ~117% FCF conversion of adjusted net income — genuinely capital-light, high-margin, strong-cash.

The Up-C fish-hooks that adjusted EPS hides. Real cash obligations sit below the adjusted line and leak value from Class-A holders: a Tax Receivable Agreement (TRA) liability of $459.0M (RYAN owes pre-IPO owners 85% of tax-step-up savings as LLC units exchange — a growing cash drain), NCI tax distributions of ~$62–85M/year, and contingent earnouts on acquisitions (the “C” in EBITDAC). Balance-sheet NCI is $606M. LLC units are steadily exchanging into Class A — the ongoing dilution mechanism. These do not make the business low-quality, but they mean the Class-A share of free cash flow is lower than adjusted EPS implies.

Margins and the near-term. The ~32% adjusted-EBITDAC margin is durable and among the best in broking, but FY2026 is guided down ~100–150bps on rate pressure, talent-hire absorption (accretive only in 2–3 years), lower fiduciary investment income (as rates fall), and higher benefits costs. Management launched Project Empower — a ~$160M restructuring through 2028 for ~$80M/year of savings by 2029 — a defensive cost push launched as growth decelerates.

Balance sheet — levered, and the cushion thinned. Net debt rose from ~$1.14B (FY23) to ~$3.2B, now ~3.3x net / ~3.5x gross adjusted EBITDAC (up from ~1.8x), with interest expense $222.4M. That is mid-range for a broker (BRO ~1–2x, AJG ~2.5–3x, Amwins/Baldwin ~5–6x) and manageable — but it doubled just as EBITDAC growth slowed, leaving less margin for error. Tangible common equity is negative (goodwill/intangibles ~$4.84B).

Verdict (§7.5): a genuinely high-quality, capital-light, ~32%-margin, strong-FCF distributor — with three honest caveats. Organic is fading and FY26 margins are guided to contract; adjusted EPS overstates Class-A economics via TRA/NCI leakage; and leverage doubled into the slowdown. The economics scale beautifully in an up-cycle; this is the down-cycle stress test.

7. Capital Allocation (§7.6)

A founder-built roll-up with a real sourcing engine — and a top-of-cycle timing problem. RYAN deploys its capital-light cash flow (plus debt) into a disciplined-looking tuck-in and platform M&A machine: ~$2.7B across ~12 deals in 2023–2025, with executive incentives tied to TSR CAGR + adjusted-EBITDAC margin + organic CAGR (good alignment). The sourcing engine and integration record are genuine strengths.

The timing is the weak point. The two largest recent deals — US Assure (Sept-2024, ~$1.18B; builder’s-risk MGU) and Velocity Risk (Feb-2025, ~$569M; catastrophe-property MGU) — were large, property-cat-concentrated, debt-funded, and bought at high-teens-to-low-20s EBITDA multiples right as the property pricing cycle peaked. US Assure is already pressured by construction delays. This is the Marathon “rolling up at the top of the cycle” pattern: buying cyclical-peak cash flows with leverage just before the cycle turns. Roughly half of FY2025’s growth was bought, and the acquired mix-shift into the high-margin MGU segment flatters the reported margin trajectory.

Deleveraging and capital return. Net leverage doubled to ~3.3–3.5x funding the deals; management now signals a deleveraging bias. The dividend is a token ~$0.52/year (~1.3% yield). RYAN initiated its first meaningful buyback ($40M) in Q1-2026 opportunistically into the drawdown — a modest but constructive signal.

Insider alignment (a genuine positive at the lows). Pat Ryan took a ~$52M option grant funded entirely from his own holdings in Q1-2026, explicitly citing the valuation “dislocation” — a strong founder-alignment signal. The pre-IPO PE sponsor Onex fully exited (~$230M secondary, Dec-2025), clearing a multi-year overhang. No insider open-market selling into the decline.

Founder control (the governance caveat). Patrick Ryan holds 77.1% of combined voting power (12.2% Class A + 83.3% Class B); all insiders ~82.5%. This is a controlled company — Class A holders have minimal governance say. Alignment is strong (founder skin in the game), but minority-holder protections are weak, and the TRA transfers value to the pre-IPO/insider group.

Leadership. CEO Tim Turner; Executive Chairman Patrick Ryan; CFO Janice Hamilton. Notably, President Jeremiah Bickham was forced out (involuntary termination without cause, Oct-2025, ~$4.25M severance) amid the inflection, with Steve Keogh (COO) and Brendan Mulshine (CRO) named Co-Presidents — a senior-departure yellow flag.

Verdict (§7.6): a disciplined-sourcing roll-up with strong founder alignment — but poorly-timed, leverage-funded property-cat M&A at the cycle peak is the real blemish, and founder control is absolute. The insider signals at the lows (Ryan’s self-funded grant, the first buyback, Onex cleared) are constructive; the top-of-cycle deals and the doubled leverage are the fair skeptical counterpoint.

8. Changes and Headwinds — Last Two Years (§7.7)

The cyclical inflection (the core story).

• Property-cat E&S rates rolled over (−25–35%) after two benign hurricane seasons; RYAN’s straight-commission wholesale book is directly exposed.
• Organic decelerated and guidance was cut twice: +15% (Q3-25, but the 35%-margin target was first deferred) → +6.6% (Q4-25, FY26 guided high-single-digit) → Q1-26 ~11.8% (flattered) but FY26 organic cut to ~5%, Q2 “near zero,” margins guided down ~100–150bps.
• AM Best cut the U.S. E&S outlook positive→stable (Nov-2025); a broad early-2026 broker “AI-disruption” scare hit the group.

Strategic / capital.

• Top-of-cycle property MGU M&A: US Assure (~$1.18B, 2024) and Velocity (~$569M, 2025), debt-funded — leverage doubled to ~3.3–3.5x.
• Project Empower restructuring (~$160M charges → ~$80M/yr savings by 2029) — a defensive cost program launched as growth slows.
• Onex fully exited (~$230M secondary, Dec-2025) — sponsor overhang cleared.
• First buyback ($40M, Q1-26) and Pat Ryan’s ~$52M self-funded option grant citing “dislocation” — insider alignment at the lows.

Leadership. President Bickham forced out (Oct-2025) amid the inflection; Co-Presidents Keogh/Mulshine appointed. CEO Turner and Exec Chairman Ryan continue.

Verdict (§7.7): weakens the near-term thesis but does not break the structural story. The growth algorithm visibly broke (organic to ~5%, margins contracting), margin targets were repeatedly cut, and the property-heavy M&A was poorly timed — all real. But the diversification into delegated authority (47%), the intact secular E&S flow, the cleared sponsor overhang, the first buyback, and strong founder alignment offset. The key watch is Pat Ryan’s own tell — “one big storm away from adjustments” — a major catastrophe would re-firm property and reverse the narrative.

9. Risk Analysis (§7.8)

Overall risk read: the dominant risks are cyclical (property pricing, organic trough) and capital-allocation/timing (top-of-cycle levered M&A), plus the structural Up-C/founder-control caveats. None is a franchise-break or balance-sheet-solvency risk (capital-light, no underwriting risk); the realistic bad outcome is a prolonged organic trough and continued de-rating, not a blow-up. Notably, the biggest risk — property softening — is also the biggest optionality: a major cat season re-firms it.

10. Valuation Discussion (§7.9)

Use fully-diluted EV and adjusted metrics. A data trap: a third-party feed shows EV of ~$8.5B capturing only the Class-A float; the correct fully-diluted EV is ~$14.7B (~279M diluted shares → ~$11.3B cap + ~$3.2B net debt). Against FY2025 adjusted EBITDAC $966.7M and adjusted EPS $1.96: EV/adjusted-EBITDAC ~14.7–15x, adjusted P/E ~20.7x, EV/Sales ~4.8x, FCF conversion ~117%, dividend yield ~1.3%. GAAP P/E is meaningless (Up-C). On the own-history percentiles (a short, post-IPO window), RYAN sits at the 14th percentile composite (11th on sales) — its cheapest since the IPO.

Comps — a growth-adjusted discount.

(*RYAN’s organic is decelerating to ~5% guided FY26 from ~10% FY25 — the crux.) RYAN trades at a discount to slower-growing AJG and Marsh and roughly in line with a self-de-rated BRO, despite (historically) the fastest growth in the group — growth-adjusted, the cheapest broker. The discount encodes the cyclical-peak fear, higher leverage (~3.3x vs BRO ~2x), and Up-C/TRA complexity.

Embedded expectations. At ~14.7x EV/adjusted-EBITDAC and ~20x adjusted EPS on a 32%-margin distributor, the market is pricing RYAN closer to a ~7% grower than the ~10–12% organic it printed through 2025 — i.e., it underwrites the guided deceleration toward mid-single-digits as permanent. If low-double-digit organic + MGU + M&A re-establishes, ~20x on ~15% EPS growth (PEG ~1.3) is inexpensive. The bear rebuttal is the Marathon capital cycle: peak organic and margins deserve a haircut before extrapolation, so the discount is partly a rational capital-cycle discount, not pure mispricing.

Scenarios (adjusted EPS; FY25 base $1.96; analytical ranges, NO price target; all ASSUMPTION):

• Bear (~$30–36): organic settles ~4–5%, margins flat-to-down; adj EPS ~$2.25 (FY27) → ~$2.40 (FY28); multiple stays compressed at ~12–13x EBITDAC / ~14–15x adj P/E — the cyclical-trap outcome.
• Base (~$48–56): organic recovers to ~8–10% as the cycle stabilizes, margin ~33–34%; adj EPS ~$2.45–2.55 (FY27) → ~$2.85–3.00 (FY28); ~14–16x EBITDAC / ~18–19x adj P/E.
• Bull (~$62–75): organic reaccelerates to low-teens (a cat season re-firms property) + MGU/M&A, margin ~34–35%; adj EPS ~$2.65–2.80 (FY27) → ~$3.20–3.40 (FY28); re-rate to peer ~17–18x EBITDAC / ~22x adj P/E.

Verdict (§7.9): de-rated GARP — the cheapest broker growth-adjusted, at a partly-rational cyclical discount. At ~20x adjusted EPS and ~14.7x EV/EBITDAC for a capital-light, secular-E&S-tailwinded franchise, the price embeds a permanent deceleration the secular flow argues against — but the honest caveat is that you are underwriting a cyclical trough, and the discount is not pure mispricing.

11. Variant Perception (§7.10)

Consensus. Heavy sell-side coverage with mixed ratings and price targets clustered ~$48–52 (above the ~$40 price): Morgan Stanley/Barclays Overweight, KBW Outperform, UBS Buy, versus Goldman/Mizuho/Cantor Neutral and Wells Fargo Equal-Weight — the debate is precisely “de-rated compounder vs. cyclical peak.” The factor tape reads an abandoned low-vol quality name: beta 0.30, deeply negative momentum, name/cycle-specific drawdown (idiosyncratic vol ~0.36) — not a high-beta bubble deflating.

Strongest bull case. RYAN is a capital-light, 32%-margin, ~117%-FCF-conversion specialty-distribution leader (#2 wholesale, #1 managing underwriter) riding the best structural tailwind in insurance — the secular E&S migration (share 5%→24%, +10.6%/yr, largely pricing-independent) — with a growing counter-cyclical delegated-authority book (47% of revenue, contingent commissions that rise as the market softens). It has de-rated ~46% to its cheapest valuation since IPO and a growth-adjusted discount to slower peers on a cyclical property-rate reversal that a single major hurricane season could reverse (“one storm away”). The founder is aligned (self-funded option grant citing “dislocation,” first buyback), the sponsor overhang is cleared, and adjusted EPS still grew ~10% into the teeth of the decline. Own the secular franchise at a cyclical low.

Strongest bear case. The de-rating is mostly deserved: RYAN’s straight-commission wholesale book is the most property-cat-cyclical in broking, organic collapsed from mid-teens to a guided ~5% (Q2 “near zero”) with margins contracting, and the 35%-margin target was pulled. Management levered up (to ~3.3–3.5x) to buy two large property-cat MGUs at peak multiples right before the cycle turned — textbook top-of-cycle roll-up. Adjusted EPS overstates Class-A economics (a $459M TRA plus NCI distributions leak cash below the line), 77% founder voting control leaves minorities powerless, the President was just forced out, and the Marathon capital cycle says the capacity the hard market attracted will keep competing rate away. “Cheapest since IPO” on a 5-year-old, cycle-peak-anchored history is a low bar.

The 3–5 assumptions that matter most:

1. Does organic trough at mid-single-digits and reaccelerate (cyclical), or is peak growth gone (structural)?
2. Do property-cat rates stabilize/re-firm, or keep softening?
3. Do the top-of-cycle property MGUs (US Assure/Velocity) earn their price, or impair?
4. Does the secular E&S flow + delegated-authority book offset the wholesale pricing drag?
5. How much does the TRA/NCI leakage and founder control discount the equity?

What would falsify each side. Bull falsified: organic stuck at 4–5% with margins still contracting into 2027 and a property-MGU write-down — the peak was structural and ~20x is not cheap. Bear falsified: organic reaccelerates toward low-double-digits (a cat season re-firms property) with margins stabilizing and de-levering — the de-rating overshot a cyclical trough.

Net variant view. Consensus is fairly split, and correctly so. The variant point is that the market is pricing a permanent deceleration onto a franchise whose secular driver (E&S flow) is durable and whose cyclical driver (property rate) is mean-reverting — but the honest counter is that the discount is partly a rational capital-cycle haircut, the M&A was mistimed, and the Up-C/control fish-hooks are real. This is a good franchise at a cyclical low, not a mispriced compounder with no warts.

12. Fact vs. Interpretation

13. Open Questions

1. Organic trough — does FY26 organic bottom at ~5% and reaccelerate, or stay mid-single-digit into 2027?
2. Property rates — do they stabilize/re-firm (a cat season), or keep softening?
3. Property MGUs — do US Assure and Velocity earn their peak-multiple prices, or impair?
4. Margin — does the ~32% adjusted-EBITDAC margin trough and recover, or is the deferred 35% target a permanent miss?
5. Deleveraging — does net leverage track below ~3x, freeing capital for buybacks/M&A?
6. TRA/NCI drag — how much does the growing TRA and NCI distribution reduce Class-A free cash flow versus adjusted EPS?
7. Succession — Pat Ryan’s role/age and the depth of the bench after the President’s departure.

14. What Must Be True (§14)

Bull case — what must be true:

1. The organic slowdown is cyclical — organic troughs at mid-single-digits and reaccelerates as the property cycle stabilizes (or a cat season re-firms rates).
2. The secular E&S flow + delegated-authority book carry growth through the soft market, and margins trough and recover.
3. The top-of-cycle property MGUs earn their price; leverage de-levers below ~3x.
4. The market re-rates a growth-adjusted-cheap, founder-aligned franchise back toward peer multiples.

Falsification test: organic reaccelerating toward low-double-digits with margins stabilizing confirms the bull; organic stuck at 4–5% with margins contracting into 2027 falsifies it.

Bear case — what must be true:

1. The hard-market growth was a one-time cyclical peak — organic settles at mid-single-digits and margins stay compressed.
2. Property rates keep softening; the levered, top-of-cycle property MGUs disappoint/impair.
3. The Up-C/TRA/NCI leakage and founder control justify a permanent discount; ~20x adjusted EPS on a decelerating grower re-rates lower.

Falsification test: a sustained organic reacceleration with margin recovery falsifies the bear; continued sub-guide organic with margin contraction and an M&A stumble confirms it.

Synthesis. Both cases agree RYAN is a high-quality, capital-light distributor with a real secular tailwind; they disagree on whether the de-rating is a cyclical overshoot (opportunity) or a rational capital-cycle haircut on a mistimed, levered roll-up (trap). Because the balance sheet is capital-light with no underwriting risk, the realistic bad outcome is a prolonged organic trough and continued dead money, not a blow-up — and the founder is buying. The asymmetry favors patient accumulation into further weakness, underwriting the cycle (not the peak) and demanding the low-$30s for a real margin of safety against the property-rate and leverage risks.

15. Source Appendix

(Primary sources below.)

• Ryan Specialty Holdings FY2025 Form 10-K (filed 2026-02-13) — segment revenue/organic (Wholesale/Binding/Underwriting Management), adjusted EBITDAC/EPS reconciliation, Up-C structure, TRA liability, NCI, leverage, M&A, risk factors (disintermediation, pricing cycle).
• FY2024 / FY2023 Form 10-K — multi-year organic/margin trend, hard-market history.
• Q1-2026 / Q4-2025 / Q3-2025 earnings & transcripts (via ROIC.ai) — organic deceleration, two FY26 guidance cuts, property-rate commentary, margin, buyback, Empower.
• DEF 14A proxy — Pat Ryan voting control (77.1%), incentive metrics (TSR + adj-EBITDAC margin + organic CAGR), Up-C/TRA.
• Form 8-Ks / press — US Assure and Velocity acquisitions, Onex secondary exit (Dec-2025), President Bickham departure, buyback, dividend, Empower restructuring.
• ROIC.ai — income statement, enterprise value, valuation multiples (RYAN, and comps BRO/AJG/MMC); reconciled to filings (note the diluted-EV correction).
• Market data — price CSV (IPO-to-date event map), valuation-index own-history percentiles (composite 14th), news feed (analyst actions).
• FactorsToday — factor loadings (Insurance +0.73, Financials, LowVol; negative momentum; beta 0.30), related-stocks (AJG/MRSH/KNSL/AON).
• Business-quality / capital-cycle frameworks — Greenwald & Kahn, Competition Demystified; Marathon, Capital Returns (investment-research-frameworks skill).

Facts are cited to primary filings where possible; interpretations and assumptions are labeled as such throughout. Management commentary is treated as hypothesis and validated against filings, financials, and external data.

APPENDIX A — Standard Diligence Questionnaire — Ryan Specialty Holdings, Inc. (NYSE: RYAN)

Supplemental to the analysis. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked? Is the organic slowdown cyclical (property rates) or structural (peak growth gone)? How much of the growth was hard-market pricing vs. secular E&S flow? Was the levered property-MGU M&A (US Assure, Velocity) mistimed at the cycle top? Does adjusted EPS overstate Class-A economics via the TRA/NCI leakage? What does 77% founder control mean for minorities? Is ~20x adjusted EPS cheap for a decelerating grower, or a value trap?

Cyclicality & Earnings Nature

Cyclical high or low? Rolling over from a cyclical high — property E&S rates −25-35%, organic cut to ~5% (Q2 “near zero”). Earnings growth decelerating off a hard-market peak.

External or internal? The slowdown is external (property pricing cycle); the secular E&S flow and MGU growth are internal/structural.

How stable are revenues? Recurring commissions/fees, but the wholesale book is pricing-cyclical; delegated authority (47%) is stickier and counter-cyclical.

Outlook for products/services? Secular E&S migration durable (+~8% flow); cyclical property pricing a near-term drag.

How big is the market? U.S. E&S ~$130B DPW (2024), ~10.6% CAGR; wholesale/MGU a concentrated oligopoly at the top.

Business Quality & Competitive Moat

More or less competitive? More at the margin — retail brokers internalizing E&S, MGA proliferation (PE-funded), carriers eyeing disintermediation.

How profitable (ROIC/ROE)? Capital-light, ~32% adjusted-EBITDAC margin, ~117% FCF conversion — high return on tangible capital; GAAP ROE distorted by Up-C.

How profitable is the industry / barriers? High-margin distribution; barriers are scale, brand/talent, and delegated-authority stickiness (deepest in MGU).

Easily understood? The model is simple; the Up-C/TRA/NCI accounting is not — requires adjusted metrics.

Undermined by foreign low-cost labor? No — relationship/expertise-driven US specialty distribution.

Do brands matter? Yes — the Ryan name and producer talent attract flow; delegated-authority reputation matters to carriers.

Switching costs? Moderate — sticky in MGU (contractual delegated authority, programs), lower in transactional wholesale.

Financial Condition & Balance Sheet

Assets not on the balance sheet? Producer relationships, carrier panels, and delegated-authority IP exceed book (tangible equity is negative — goodwill/intangibles ~$4.84B).

Off-balance-sheet liabilities? TRA liability ($459M), contingent earnouts, NCI tax distributions — real cash claims below the adjusted line.

How conservative is the accounting? Adjusted metrics are standard for brokers but flatter Class-A economics; contingent-consideration (“C” in EBITDAC) and Up-C require care. GAAP is uninformative.

How capex-hungry? Very light — a distribution/services model; capex minimal.

Capital Allocation & Management

How much FCF, how used? Strong (~117% conversion of adj NI, CFO $643.7M). Priorities: M&A > deleveraging > token dividend > opportunistic buyback ($40M, first).

Significant acquisitions? US Assure (~$1.18B, 2024), Velocity (~$569M, 2025), Castel, Innovisk + tuck-ins; ~$2.7B/12 deals 2023-25, high-teens-low-20s x EBITDA. Property MGUs bought at cycle top.

Buying back shares? Just initiated — $40M in Q1-26, opportunistic into the drawdown.

Issuing stock to insiders? Ongoing LLC-unit exchanges (Up-C dilution) + M&A stock; SBC ~2.3% of revenue.

Compensation policy? PSUs on TSR CAGR + adj-EBITDAC margin + organic CAGR — good alignment.

Motivations of management? Founder-controlled (Pat Ryan 77% vote); strong alignment (Ryan’s ~$52M self-funded option grant citing “dislocation”); CEO Tim Turner; President Bickham forced out (2025).

Valuation & Market Data

ADR, MLP, or K-1? No — a Delaware C-corp (Up-C holding structure over an LLC); Class A common on NYSE, standard 1099. (LLC unitholders receive K-1s; public Class A holders do not.)

Dividend policy? Token ~$0.52/yr (~1.3% yield), initiated 2024.

How profitable? High-margin capital-light distributor (~32% adj EBITDAC); GAAP muddied by Up-C/NCI.

Net income vs. cash flow? Adjusted NI backed by strong FCF (~117%), but TRA/NCI cash claims sit below it — Class-A FCF < adjusted EPS implies.

Risks & Downside

What would cause the stock to decline? Continued property-rate softening / organic staying weak; a property-MGU impairment; the cyclical peak proving structural; TRA/leverage/control discount.

Catastrophic loss risk? Very low — no underwriting risk, capital-light, diversified.

Total loss? Effectively nil — the risk is a prolonged trough/de-rating, not a wipeout.

Recent News & Events

Has the environment changed? Yes — property E&S hard market softening; organic guidance cut twice; broker-sector AI-disruption scare.

Significant acquisitions? US Assure (2024), Velocity (2025) — property MGUs at cycle top.

Change in accounting policies? None material; Project Empower restructuring (~$160M charges → ~$80M/yr savings by 2029).

Recent changes? FY26 organic cut to ~5%; President Bickham forced out; Onex sponsor exited (Dec-2025); first buyback; Pat Ryan self-funded option grant.

APPENDIX B — Source Appendix — Ryan Specialty Holdings, Inc. (NYSE: RYAN)

Primary sources prioritized. Facts cited to filings where possible; interpretations/assumptions labeled in the memo. Access date: 2026-07-10.

Primary — SEC Filings (Ryan Specialty Holdings, Inc., CIK 0001849253)

• FY2025 Form 10-K (filed 2026-02-13; year ended 2025-12-31) — three-specialty reporting (Wholesale Brokerage / Binding Authority / Underwriting Management), organic-growth by specialty, adjusted EBITDAC and adjusted-EPS reconciliation, Up-C structure and non-controlling interest, Tax Receivable Agreement liability, leverage/debt schedule, M&A note (US Assure/Velocity/Castel), risk factors (disintermediation, pricing cycle, founder control). Local: output/RYAN/sources/10-K/2026-02-13_ryan-20251231.htm.
• FY2024 / FY2023 Form 10-K — multi-year organic/margin trend, hard-market history, earlier deals. .../2025-02-21_ryan-20241231.htm, .../2024-02-28_ryan-20231231.htm.
• Q1-2026 Form 10-Q — organic deceleration, FY26 guidance cut, margin, buyback. output/RYAN/sources/10-Q/.
• DEF 14A proxy — Patrick Ryan voting control (77.1%), all-insider ownership (~82.5%), incentive metrics (TSR CAGR + adj-EBITDAC margin + organic CAGR), Up-C/TRA mechanics. output/RYAN/sources/DEF_14A/.
• Form 8-Ks / press — Q3-25/Q4-25/Q1-26 earnings and guidance cuts; US Assure (Sept-2024) and Velocity (Feb-2025) acquisitions; Onex secondary exit (Dec-2025); President Bickham departure (Oct-2025); dividend; $40M buyback; Project Empower restructuring. output/RYAN/sources/8-K/.
• Form 4s / secondary-offering prospectuses — pre-IPO holder sell-downs (Onex fully exited); Pat Ryan’s Q1-26 self-funded option grant; no insider open-market selling into the decline. EDGAR.

Primary — Earnings-Call Transcripts (via ROIC.ai)

• Q1-2026 (4/30/26) / Q4-2025 (2/12/26) / Q3-2025 (10/30/25) — organic-growth trajectory and the two FY26 guidance cuts (to ~5% organic, Q2 “near zero”), property-cat rate softening (−25-35%), casualty bifurcation, delegated-authority (47%) counter-cyclical offset, margin guide (−100-150bps, 35% target deferred), leverage, buyback, Empower. (Exec Chairman Patrick Ryan; CEO Tim Turner; CFO Janice Hamilton; commentary from Greenspan.)

Quantitative Data Sources

• ROIC.ai — income statement, enterprise value, valuation multiples (RYAN, and comps BRO/AJG/MMC); reconciled to filings. NOTE: ROIC’s headline EV captures only the Class-A float — the correct fully-diluted EV (~$14.7B, ~279M diluted shares) was recomputed.
• Market data — price CSV (IPO-to-date, for the event map); valuation-index own-history percentiles (composite 14th, P/S 11th, P/B 3.4th); news feed (heavy July-2026 analyst actions). CSV local: output/RYAN/2026-07-10/_scratch/RYAN_price.csv.
• FactorsToday — factor loadings (Insurance +0.73, Financials +0.53, LowVol; negative Momentum; beta 0.30), leaderboard (negative RS all horizons; ~flat 3-yr), related-stocks (AJG/MRSH/KNSL/AON/ACGL/MKL), specific-vol (~0.36).
• EDGAR / edgar.sh — corpus enumeration; Up-C share-count and TRA reconciliation.

Secondary — Press & Third-Party

• Q1-2026 guidance / “near-zero Q2 growth on property drag” — Coverager, InsuranceBusinessMag, 2026.
• Analyst actions (July 2026) — Goldman Neutral, UBS Buy $50-52, Morgan Stanley/Barclays Overweight, KBW Outperform, Mizuho/Cantor/Wells Neutral/EW (targets not reproduced in the memo body per no-price-target rule).
• US Assure and Velocity acquisition releases; Onex secondary-offering release (Dec-2025).

Analytical Frameworks

• Greenwald & Kahn, Competition Demystified — moat taxonomy (scale in the E&S niche + intangibles/brand-talent + switching costs; deepest in MGU), and the caveat that fast market growth erodes scale barriers.
• Marathon Asset Management (Edward Chancellor, ed.), Capital Returns — supply-side capital-cycle analysis (the hard market attracting the capacity now competing rate away; “rolling up at the top of the cycle” via debt-funded property-cat MGUs).
• (via the repository’s investment-research-frameworks skill.)